SCHEMBL6232872

SCHEMBL6232872

COC1NC(=O)NC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796662 0.75
SCHEMBL6234607 0.75 TSHR (0.43)
SCHEMBL6230585 0.75 TSHR (0.43)
SCHEMBL631670 0.73 TSHR (0.41)
SCHEMBL6233114 0.72 ALDH1A1 (0.46)
SCHEMBL2064740 0.71 TSHR (0.39)
SCHEMBL10716626 0.70 TSHR (0.38)
SCHEMBL11537769 0.70 TSHR (0.47)
SCHEMBL1332682 0.69 TSHR (0.42)
SCHEMBL11771126 0.69 TSHR (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5236978-A None JP disclosed
EP-3639821-B1 CARCINOGENESIS INHIBITOR NAT CANCER CT (JP) 2024-08-28 EP disclosed
CN-114808052-B Cyanide-free conversion method for cyanide silver plating solution 中国机械总院集团武汉材料保护研究所有限公司 2024-03-15 CN disclosed
CN-110740729-B Carcinogenesis inhibitor 国立研究开发法人国立癌症研究中心 2023-05-16 CN disclosed
US-11464762-B2 Carcinogenesis inhibitor NATIONAL CANCER CENTER (JP) 2022-10-11 US disclosed
CN-114808052-A Cyanide-free conversion method of cyanide silver plating solution 武汉材料保护研究所有限公司 2022-07-29 CN disclosed
US-20200276163-A1 CARCINOGENESIS INHIBITOR NATIONAL CANCER CENTER (JP) 2020-09-03 US disclosed
EP-3639821-A1 CARCINOGENESIS INHIBITOR National Cancer Center (JP) 2020-04-22 EP disclosed
CN-109468304-A The mutant of Hydantoinase 赢创工业化学有限公司 2019-03-15 CN disclosed
EP-1243261-B1 Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia NIPPON ZOKI PHARMACEUTICAL CO (JP) 2005-04-27 EP disclosed
EP-1018339-B1 Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. NIPPON ZOKI PHARMACEUTICAL CO (JP) 2003-05-02 EP disclosed
US-20020147228-A1 AGENT FOR HYPOALBUMINAEMIA NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2002-10-10 US disclosed
EP-1243261-A1 Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2002-09-25 EP disclosed
US-6451831-B1 TREATMENT WITH HYDANTOIN DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2002-09-17 US disclosed
US-6251929-B1 ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) 2001-06-26 US disclosed
EP-0780125-B1 Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals NIPPON ZOKI PHARMACEUTICAL CO (JP) 2001-04-18 EP disclosed
US-6197806-B1 USING A HYDANTOIN DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2001-03-06 US disclosed
EP-1018339-A1 Therapeutic agent for intractable vasculitis NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2000-07-12 EP disclosed
EP-0780125-A2 Pharmaceutical composition containing a hydantoin derivative and use of said derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed
JP-H05236978-A PRODUCTION OF O-METHYL-L-TYROSINE AND L-3-(1-NAPHTHYL) ALANINE AJINOMOTO CO INC 1993-09-17 JP disclosed